HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

Autor: MARTÍNEZ-PIÑEIRO, JOSÉ A., MARTÍNEZ-PIÑEIRO, LUIS, SOLSONA, EDUARDO, RODRÍGUEZ, RAFAEL HERNÁNDEZ, FERNÁNDEZ GÓMEZ, JESÚS MARÍA, MARTÍN, MARCELINO GONZÁLEZ, MOLINA, JESÚS RODRÍGUEZ, COLLADO, ANABEL GIMENO, FLORES, NICOLÁS, ISORNA, SANTIAGO, PERTUSA, CARLOS, RABADÁN, MARIANO, ASTOBIETA, ANDER, CAMACHO, JOSÉ EMILIO, ARRIBAS, SALVADOR, MADERO, ROSARIO

Publikováno v: In The Journal of Urology 2005 174(4) Part 1:1242-1247

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

Autor: Jesus Fernandez-Gomez, Jesus Rodriguez-Molina, C. Pertusa, Miguel Blas, M. Unda, Eduardo Solsona, M. Gonzalez, Anabel Gimeno, Luis Martínez-Piñeiro, Antonio Ojea, Mariano Rabadan, Santiago Isorna, Jose Emilio Camacho, Ander Astobieta, J.A. Portillo, P. Muntanola, Martínez-Piñeiro Ja, Rosario Madero, Manuel Montesinos

Publikováno v: International braz j urol, Volume: 37, Issue: 5, Pages: 671-672, Published: OCT 2011
International Brazilian Journal of Urology, Vol 37, Iss 5, Pp 671-672 (2011)
International braz j urol v.37 n.5 2011
International Braz J Urol
Sociedade Brasileira de Urologia (SBU)
instacron:SBU

Background European Organization for Research and Treatment of Cancer (EORTC) risk tables only included 171 patients treated with bacillus Calmette-Guerin (BCG) for non–muscle-invasive bladder cancer (NMIBC). Objective To evaluate the external vali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106edbb0be3a0ba9640126d71576c546
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000500025&lng=en&tlng=en

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

Autor: C. Pertusa, Santiago Isorna, Mariano Rabadan, Rosario Madero, Marcelino Gonzalez Martin, For Club Urológico Español de Tratamiento Oncológico (Cueto), Ander Astobieta, Jesús María Fernández Gómez, Rafael Hernandez Rodríguez, Salvador Arribas, Jesús Rodríguez Molina, Luis Martínez-Piñeiro, Martínez-Piñeiro Ja, Eduardo Solsona, Anabel Gimeno Collado, Nicolas Flores, Jose Emilio Camacho

Publikováno v: The Journal of urology. 174(4 Pt 1)

We determined if a third of the dose of intravesical bacillus Calmette-Guerin (BCG) has the same efficacy than a standard dose for decreasing the risk of recurrence and progression after transurethral resection in patients with superficial high risk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4091ad04a8f16e121d23d296702e8029
https://pubmed.ncbi.nlm.nih.gov/16600806